Longevity FAST aims to disrupt traditional longevity research funding by providing decisions within nine days of application, significantly faster than typical funding cycles.

NFX encourages applications from startups at any stage of development, recognizing that innovative ideas can emerge from unconventional sources.

NFX, a venture capital firm based in Silicon Valley, has launched the Longevity FAST initiative to support early-stage startups focused on extending human lifespan.

This initiative responds to the growing interest in longevity research and aims to bridge the gap between lifespan and healthspan, which is often plagued by chronic illnesses.

Longevity FAST emphasizes 'hardcore longevity' projects that seek transformative breakthroughs, with aspirations of enabling individuals to live to 160 years or beyond.

Key challenges for these ambitious projects include cellular rejuvenation, epigenetic reprogramming, and disease prevention, which the program aims to support despite their complexity.

The program offers between $1 million and $3 million in pre-seed and seed funding through a Simple Agreement for Future Equity (SAFE), making it accessible to innovative startups.

Unlike traditional biotech funding that often favors incremental improvements, Longevity FAST is designed to support bold, transformative ideas.

Startups accepted into the program will benefit from mentorship and access to a network of experienced investors, helping them refine their strategies and attract further investment.

The initiative includes live pitches for finalists, allowing founders to present their visions directly to NFX's decision-makers, fostering a culture of innovation.

The focus on enhancing healthspan reflects a dual goal of increasing both the duration and quality of life, free from chronic diseases.

As the longevity sector matures, initiatives like Longevity FAST are essential for challenging norms and advancing efforts in lifespan and healthspan extension.